Try our Advanced Search for more refined results
Life Sciences
- 
									October 23, 2025
									Ex-Exec Accused Of Stealing IVF Co.'s Trade SecretsThe co-founder of a Garden State genetic testing company abruptly quit, deleted all the data on his company laptop — including the only copy of some materials — then took the trade secrets to help a competitor, according to a lawsuit filed in New Jersey federal court. 
- 
									October 23, 2025
									Eli Lilly Says Pharmacy Mass-Producing Weight Loss DrugDrugmaker Eli Lilly is suing a compounding pharmacy in Texas federal court, alleging the pharmacy ripped off its lucrative weight loss drug, began mass-producing it, and made as much as $2 million per month last year from its misdeeds. 
- 
									October 23, 2025
									Avadel, Jazz Settle Sleep Disorder Drug ClaimsAvadel Pharmaceuticals has announced it reached a global settlement with Irish rival Jazz Pharmaceuticals to dismiss their lawsuits against each other that alleged patent and antitrust violations related to sleep disorder drug Lumryz. 
- 
									October 23, 2025
									Del. Startup Accuses Ex-CEO In Chancery Of Stock SchemeA Delaware pharmaceutical startup has sued its former CEO in the Delaware Chancery Court, accusing him of secretly enriching himself through unauthorized stock issuances and deceptive loans. 
- 
									October 23, 2025
									Feds, Ex-Magellan CEO Still Split Over Sentencing FactorsLawyers for a former Magellan Diagnostics CEO and the government are still at odds over whether a judge should consider the product mislabeling charge she pled guilty to in March to be tantamount to fraud — an assertion the defense says is an attempt by prosecutors to "shoehorn" in allegations never put to proof. 
- 
									October 23, 2025
									Buyers Sue Colgate Over Lead Found In Kids' ToothpasteA proposed class of buyers is suing Colgate-Palmolive Co. in California federal court, alleging that it sold children's toothpaste that contains substantial amounts of lead without warning consumers. 
- 
									October 23, 2025
									5th Circ. Revives Religious Bias Suit Over DOD Vaccine PolicyThe Fifth Circuit breathed new life into a proposed class action claiming the U.S. Department of Defense unlawfully slow-walked civilian employees' requests for religious exemptions from its COVID-19 vaccination directive, saying the mandate getting rescinded didn't nullify the lawsuit. 
- 
									October 22, 2025
									Novo Nordisk Paid Patient Benefits, Not Bribes, Jury HearsNovo Nordisk Inc. paid benefits to patients with a rare form of hemophilia and not bribes as a group of plaintiffs in an alleged kickback scheme have claimed, a Washington jury was told Wednesday during emotional testimony on the third day of a multiweek trial. 
- 
									October 22, 2025
									Judge Voids HHS Rule Banning Gender Identity DiscriminationA Mississippi federal judge on Wednesday struck down a Biden-era U.S. Department of Health and Human Services rule that protected gender-affirming care under the Affordable Care Act, ruling that federal officials exceeded their authority by broadening the definition of sex discrimination to cover gender identity. 
- 
									October 22, 2025
									Bristol-Myers $450M Payment Dispute Heads To ArbitrationA judge sitting for Delaware's Court of Chancery has sent to arbitration allegations from shareholders of a small biotechnology company acquired by Bristol-Myers Squibb that the pharmaceutical giant used trickery to avoid paying up to $450 million in milestone payments. 
- 
									October 22, 2025
									Judge Tosses Ingenus Suit Over Leukemia Treatment PatentA Delaware federal judge has agreed to throw out a lawsuit accusing Hetero Labs Ltd. of infringing a patent covering a treatment for lymphoma and leukemia, pointing out that an Illinois federal court in a separate case already found the patent to be invalid. 
- 
									October 22, 2025
									Purdue Fights Baltimore Objection Ahead Of Ch. 11 Plan TrialPurdue Pharma LP told a New York bankruptcy judge on Wednesday it is concerned a recent objection to its Chapter 11 plan brought by the city of Baltimore could disrupt its case just weeks before the drugmaker is set to begin trial on a deal that creditors overwhelmingly support. 
- 
									October 22, 2025
									Latham Adds BCLP Environmental Atty In SF Bay AreaLatham & Watkins LLP is expanding its environmental team, announcing Wednesday it is bringing in a Bryan Cave Leighton Paisner LLP expert on chemicals, especially "forever chemicals," as a partner in its San Francisco Bay Area offices. 
- 
									October 22, 2025
									Unions Pursue More Protection For Federal Workers In ShutdownEight unions asked a California federal judge to step up the level of protection she provided to thousands of federal workers' jobs during the government shutdown, urging her to expand the number of jobs she's protecting and turn a temporary restraining order into a preliminary injunction. 
- 
									October 22, 2025
									Trump Flouted Clean Air Act With Rule Delay, Enviro Orgs. SayPresident Donald Trump violated the Clean Air Act when he delayed deadlines to comply with air pollution standards for companies in the chemical manufacturing industry, green groups alleged in Washington federal court Wednesday. 
- 
									October 22, 2025
									5 Firms Guide $2.1B Alkermes-Avadel Sleep Medicine DealDublin-based Alkermes PLC has agreed to buy Avadel Pharmaceuticals PLC, a fellow Irish drugmaker focused on sleep medicine, in an all-cash deal valuing Avadel at about $2.1 billion, the companies said on Wednesday. 
- 
									October 22, 2025
									NC Biz Court Bulletin: COVID Coverage, A Suspect SignatureThe North Carolina Business Court has rounded the corner into fall with insurance disputes over COVID-19 coverage at a chain of outlet malls and the theft of over $900,000 in legal THC reportedly stolen from a warehouse in the Southwest. 
- 
									October 22, 2025
									Naked Whey Sued Over Reports Of Lead In Protein PowderA proposed class of consumers is suing Naked Whey Inc. in California federal court, alleging that it knew its products contained, or risked containing, dangerous heavy metals like lead, but advertised them as clean, tested and safe protein supplements. 
- 
									October 21, 2025
									Novo Nordisk Says Officials Not Qualified To Doubt Drug BillsAttorneys for Novo Nordisk Inc. on Tuesday sought to undercut witness testimony that Medicaid claims in Washington state for the company's hemophilia drug NovoSeven were shockingly high, leading one state auditor to suspect fraud. 
- 
									October 21, 2025
									Patent Landscape Shifts As Squires Takes On Key PTAB RoleThe announcement that U.S. Patent and Trademark Office Director John Squires will now make all decisions on whether to institute America Invents Act patent reviews is expected to reshape litigation, by leading fewer accused companies to file challenges, attorneys say. 
- 
									October 21, 2025
									Judge Trims Pharma Co. Claims Against Ex-EmployeesA Florida federal judge has narrowed pharmaceutical company Lupin Inc.'s lawsuit accusing a rival of stealing trade secrets, freeing a pair of former employees of claims that they breached their fiduciary duties by allegedly swiping the company's confidential information. 
- 
									October 21, 2025
									3rd Circ. Reinstates Union Rep's Pharmacy Fraud ChargesThe Third Circuit said Tuesday that it had revived charges against a union representative at a telecommunications company after finding that federal prosecutors sufficiently alleged that the rep submitted false claims to a pharmacy benefits manager for medically unnecessary testing and medicine. 
- 
									October 21, 2025
									10x Genomics Hits Illumina With 2 Gene Tech Patent Suits10x Genomics accused biotech giant Illumina Inc. of infringing nine genetic sequencing patents in two Delaware federal lawsuits Tuesday, arguing that Illumina knew of at least one of the patents because it was involved in a $31 million verdict against a different company that is well-known in the biology space. 
- 
									October 21, 2025
									Nexus Can't Pursue IP Dropped Before Trial, Del. Judge SaysWhen Nexus Pharmaceuticals Inc. dropped patent claims to narrow its suit against Exela Pharma Sciences LLC, it lost the ability to assert them later on, a Delaware federal judge said Tuesday. 
- 
									October 21, 2025
									Regeneron, Rival End Patent Fight Over Eye Med BiosimilarRegeneron and a South Korea-based rival it had accused of infringing several patents covering the U.S. biotech company's top eye medication Eylea have agreed to a settlement to put an end to the case filed in West Virginia federal court. 
Expert Analysis
- 
								Series Power To The Paralegals: How And Why Training Must Evolve  Empowering paralegals through new models of education that emphasize digital fluency, interdisciplinary collaboration and human-centered lawyering could help solve workforce challenges and the justice gap — if firms, educators and policymakers get on board, say Kristine Custodio Suero and Kelli Radnothy. 
- 
								Series Playing Softball Makes Me A Better Lawyer  My time on the softball field has taught me lessons that also apply to success in legal work — on effective preparation, flexibility, communication and teamwork, says Sarah Abrams at Baleen Specialty. 
- 
								
								5 Years In, COVID-19 Fraud Enforcement Landscape Is Shifting  As the government moves pandemic fraud enforcement from small-dollar individual prosecutions to high-value corporate cases, and billions of dollars remain unaccounted for, companies and defense attorneys must take steps now to prepare for the next five years of scrutiny, says attorney David Tarras. 
- 
								
								Fed. Circ. In August: A Framework For AIA Derivation Disputes  In Global Health Solutions v. Selner, the Federal Circuit established how to assess derivation challenges under the America Invents Act's first-to-file system, making it easier for petitioners to determine a challenge's odds of success, say attorneys at Knobbe Martens. 
- 
								
								USPTO's Track One A Reliable Patent Pathway Amid Backlog  As the U.S. Patent and Trademark Office faces a backlog of unexamined utility, plant and reissue patent applications, patent applicants should consider utilizing the USPTO's Track One Program, which not only expedites the process but also increases the likelihood of working with more senior examiners, says Ryan Schermerhorn at Marshall Gerstein. 
- 
								
								Vanda Ruling Opens Door For Contesting FDA Drug Denials.jpg)  The D.C. Circuit's recent decision in Vanda Pharmaceuticals v. U.S. Food and Drug Administration creates new opportunities and considerations for drug companies navigating the FDA approval process, establishing that litigation is an option when the FDA refuses to hold a hearing, say attorneys at Polsinelli. 
- 
								Series Law School's Missed Lessons: Mastering Time Management-media.jpg)  Law students typically have weeks or months to prepare for any given deadline, but the unpredictability of practicing in the real world means that lawyers must become time-management pros, ready to adapt to scheduling conflicts and unexpected assignments at any given moment, says David Thomas at Honigman. 
- 
								
								Rare Del. Oversight Ruling Sends Governance Wake-Up Call  An unusual ruling from the Delaware Court of Chancery recently allowed Caremark oversight claims to proceed against former executives of a company previously known as Teligent, sending a clear reminder that boards and officers must actively monitor and document oversight efforts when addressing mission-critical risks, say attorneys at WilmerHale. 
- 
								
								How Hyperlinks Are Changing E-Discovery Responsibilities  A recent e-discovery dispute over hyperlinked data in Hubbard v. Crow shows how courts have increasingly broadened the definition of control to account for cloud-based evidence, and why organizations must rethink preservation practices to avoid spoliation risks, says Bree Murphy at Exterro. 
- 
								
								Pharma Copay Programs Raise Complex Economic Questions  The growing prevalence of copay accumulator and maximizer programs in the pharmaceutical industry is drawing increased scrutiny from patients, advocacy groups, lawmakers and courts, bringing complex questions about how financial responsibility for prescription drug purchases is determined and complicating damages assessments in litigation, say analysts at Analysis Group. 
- 
								
								State False Claims Acts Can Help Curb Opioid Fund Fraud  State versions of the federal False Claims Act can play an important role in policing the misuse of opioid settlement funds, taking a cue from the U.S. Department of Justice’s handling of federal fraud cases involving pandemic relief funds, says Kenneth Levine at Stone & Magnanini. 
- 
								
								Beaming Up Lessons From William Shatner's Failed Patent Bid  In a tale that boldly goes where few celebrity inventors have gone before, William Shatner's unsuccessful attempt to patent a smartphone file organization system offers insights about potential pitfalls to avoid in patent applications, say attorneys at King & Spalding. 
- 
								
								The Pros And Cons Of Levying Value-Based Fees On Patents  The potential for a recurring, value-based maintenance fee on patents, while offering some benefits, raises several complications, including that it would likely exceed the U.S. Patent and Trademark Office's statutory authority and reduce research and development activities in the U.S., says Sandip Patel at Marshall Gerstein. 
- 
								Series Writing Musicals Makes Me A Better Lawyer  My experiences with writing musicals and practicing law have shown that the building blocks for both endeavors are one and the same, because drama is necessary for the law to exist, says Addison O’Donnell at LOIS Law. 
- 
								
								Between The Lines Of EPO's Adoption Of Color Drawings  The European Patent Office's decision to accept patent drawings in color starting in October may enhance clarity in technical disclosures and streamline the examination process, and could also enable new patent filing strategies for international applicants, say attorneys at Miller Canfield.